Cantor Fitzgerald keeps an Overweight rating on Vera Therapeutics (VERA) with a $100 price target after non-profit Kidney Disease: Improving Global Outcomes released updated guidelines for immunoglobulin A nephropathy. The firm sees “direct positive implications” for Vera’s atacicept, saying the drug has shown the ability to reduce pathogenic IgA and glomerular injury. Cantor continues to believe the size of the IgA market remains underestimated. Vera in afternoon trading is up 7% to $26.15.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Reports Progress in Clinical Trials
- Vera Therapeutics Signs New Sales Agreement with TD Securities
- Vera Therapeutics reports Q2 EPS ($1.20), consensus (62c)
- Vera Therapeutics announces anticipated upcoming milestones
- Vera Therapeutics sees cash funding operations through launch of atacicept